Fingolimod suppresses bone resorption in female patients with multiple sclerosis

• Fingolimod suppresses bone resorption in patients with MS.
• Suppression of bone resorption by fingolimod is prominent in female MS patients.
• Fingolimod may have a beneficial effect on bone mass loss in female MS patients.

Fingolimod is a sphingosine-1-phosphate receptor agonist used to inhibit the inflammatory activity of multiple sclerosis (MS), and has been shown to suppress osteoporosis in mouse models. In this study, levels of bone turnover markers were quantified in serum and urine samples from MS patients treated with fingolimod. Compared with untreated MS patients and healthy controls, fingolimod-treated MS patients had a significantly lower level of the bone resorption marker type I collagen cross-linked N-telopeptide in urine. This finding was prominent in female but was not seen in male subjects. Our results suggest that fingolimod may have a beneficial effect on bone mass loss in female MS patients.

Figure optionsDownload high-quality image (137 K)Download as PowerPoint slide